title: The utility of a multidomain assessment of steroid response for predicting clinical response to omalizumab.
authors.affiliation: Respiratory Paediatrics, Royal Brompton Hospital, London, United Kingdom; Inflammation, Repair and Development, National Heart & Lung Institute, Imperial College London, London, United Kingdom. Electronic address: l.fleming@imperial.ac.uk.
authors.forename: Louise
authors.initials: L
authors.lastname: Fleming
authors.affiliation: Respiratory Paediatrics, Royal Brompton Hospital, London, United Kingdom.
authors.forename: Maria
authors.initials: M
authors.lastname: Koo
authors.affiliation: Respiratory Paediatrics, Royal Brompton Hospital, London, United Kingdom; Respiratory Paediatrics, King's College Hospital, London, United Kingdom.
authors.forename: Cara J
authors.initials: CJ
authors.lastname: Bossley
authors.affiliation: Respiratory Paediatrics, Royal Brompton Hospital, London, United Kingdom; Inflammation, Repair and Development, National Heart & Lung Institute, Imperial College London, London, United Kingdom.
authors.forename: Prasad
authors.initials: P
authors.lastname: Nagakumar
authors.affiliation: Respiratory Paediatrics, Royal Brompton Hospital, London, United Kingdom; Inflammation, Repair and Development, National Heart & Lung Institute, Imperial College London, London, United Kingdom.
authors.forename: Andrew
authors.initials: A
authors.lastname: Bush
authors.affiliation: Respiratory Paediatrics, Royal Brompton Hospital, London, United Kingdom; Inflammation, Repair and Development, National Heart & Lung Institute, Imperial College London, London, United Kingdom.
authors.forename: Sejal
authors.initials: S
authors.lastname: Saglani
mesh_terms: D000293:Adolescent; D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D001249:Asthma / Q000175:diagnosis* / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D015415:Biomarkers / Q000032:analysis; D002648:Child; D005260:Female; D006801:Humans; D009241:Ipratropium / Q000627:therapeutic use; D020024:Leukotriene Antagonists / Q000627:therapeutic use; D008297:Male; D009569:Nitric Oxide / Q000032:analysis; D000069444:Omalizumab / Q000627:therapeutic use*; D011379:Prognosis; D013147:Spirometry; D013183:Sputum / Q000737:chemistry; D014221:Triamcinolone / Q000627:therapeutic use*; D014797:Vital Capacity
chemical_list: D000318:Adrenergic beta-Agonists; D018927:Anti-Asthmatic Agents; D015415:Biomarkers; D020024:Leukotriene Antagonists; D014221:Triamcinolone; D000069444:Omalizumab; D009569:Nitric Oxide; D009241:Ipratropium